Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 5Leukemia, Myelomonocytic, Chronic 3Solid Tumor 1Melanoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Cytopenia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 43venetoclax 30Cytarabine 25fludarabine 22fludarabine phosphate 17Azacitidine 16Mycophenolic Acid 13Whole-Body Irradiation 12Dexamethasone 12ruxolitinib 11Rituximab 11Busulfan 11Vincristine 10Methotrexate 10Etoposide 10Tacrolimus 9Daunorubicin 9Mercaptopurine 8Filgrastim 8Dasatinib 8ibrutinib 7Prednisone 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Granulocyte Colony-Stimulating Factor 7Doxorubicin 7Decitabine 7pegaspargase 6blinatumomab 6Mesna 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × cedazuridine × 1 year × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡